Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
64
Participants
Timeline
Start Date
September 1, 2015
Primary Completion Date
September 30, 2017
Study Completion Date
December 31, 2017
Conditions
Biliary Tract Neoplasms
Interventions
DRUG
Irinotecan
DRUG
Capecitabine
Trial Locations (1)
310006
First affiliated hospital, Zhejiang University, Hangzhou
All Listed Sponsors
lead
Zhejiang University
OTHER
NCT02558959 - Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer | Biotech Hunter | Biotech Hunter